Compare PMT & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | SGP |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 891.1M |
| IPO Year | 2009 | 2026 |
| Metric | PMT | SGP |
|---|---|---|
| Price | $9.68 | $28.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $13.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.1M | 60.3K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $351,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $24.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.05 | $17.06 |
| 52 Week High | $13.80 | $30.56 |
| Indicator | PMT | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 72.48 |
| Support Level | $9.11 | $24.87 |
| Resistance Level | $9.83 | $29.11 |
| Average True Range (ATR) | 0.17 | 1.22 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 86.24 | 94.88 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.